Deutsche Bank AG Grows Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Deutsche Bank AG grew its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 12.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 84,163 shares of the specialty pharmaceutical company's stock after purchasing an additional 9,164 shares during the quarter. Deutsche Bank AG owned approximately 0.26% of Collegium Pharmaceutical worth $2,411,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. MetLife Investment Management LLC lifted its stake in Collegium Pharmaceutical by 8.5% in the fourth quarter. MetLife Investment Management LLC now owns 19,987 shares of the specialty pharmaceutical company's stock worth $573,000 after acquiring an additional 1,558 shares during the period. Barclays PLC lifted its stake in Collegium Pharmaceutical by 152.2% in the third quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company's stock worth $2,899,000 after acquiring an additional 45,291 shares during the period. Sanctuary Advisors LLC lifted its stake in Collegium Pharmaceutical by 5.3% in the fourth quarter. Sanctuary Advisors LLC now owns 18,928 shares of the specialty pharmaceutical company's stock worth $542,000 after acquiring an additional 952 shares during the period. Amundi lifted its stake in Collegium Pharmaceutical by 188.3% in the fourth quarter. Amundi now owns 15,568 shares of the specialty pharmaceutical company's stock worth $446,000 after acquiring an additional 10,168 shares during the period. Finally, Nisa Investment Advisors LLC lifted its stake in Collegium Pharmaceutical by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock worth $71,000 after acquiring an additional 316 shares during the period.

Wall Street Analysts Forecast Growth

Several brokerages have commented on COLL. Needham & Company LLC reissued a "buy" rating and set a $46.00 price objective on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. Piper Sandler reissued a "neutral" rating and set a $37.00 price objective (up previously from $36.00) on shares of Collegium Pharmaceutical in a research report on Friday, May 9th. HC Wainwright reissued a "buy" rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. Finally, StockNews.com lowered Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Saturday, April 19th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $43.80.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ:COLL opened at $29.47 on Thursday. Collegium Pharmaceutical, Inc. has a 1-year low of $23.23 and a 1-year high of $42.29. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The business has a fifty day moving average price of $28.15 and a 200-day moving average price of $29.80. The company has a market capitalization of $946.93 million, a PE ratio of 12.70 and a beta of 0.63.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share for the quarter, missing the consensus estimate of $1.50 by ($0.01). Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The company had revenue of $177.76 million for the quarter, compared to the consensus estimate of $174.96 million. During the same quarter in the previous year, the business earned $1.45 earnings per share. Collegium Pharmaceutical's revenue was up 22.7% compared to the same quarter last year. As a group, equities analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Shirley R. Kuhlmann sold 40,000 shares of Collegium Pharmaceutical stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total value of $1,123,200.00. Following the completion of the sale, the executive vice president now directly owns 154,204 shares in the company, valued at approximately $4,330,048.32. This trade represents a 20.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Colleen Tupper sold 1,949 shares of Collegium Pharmaceutical stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $30.00, for a total value of $58,470.00. Following the completion of the sale, the chief financial officer now owns 177,195 shares of the company's stock, valued at $5,315,850. The trade was a 1.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 81,693 shares of company stock worth $2,334,994. 2.51% of the stock is owned by corporate insiders.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.